NASDAQ:IMRN Immuron Q2 2026 Earnings Report $1.10 +0.02 (+1.85%) Closing price 08/5/2026 04:00 PM EasternExtended Trading$1.10 -0.01 (-0.45%) As of 08/5/2026 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immuron EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuron Revenue ResultsActual Revenue$1.40 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuron Announcement DetailsQuarterQ2 2026Date2/25/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsImmuron's next earnings date is estimated for Friday, August 28, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Immuron Earnings HeadlinesImmuron CEO Showcases Gut-Targeted Antibody Platform at TechKnow Invest RoadshowJuly 26, 2026 | tipranks.comImmuron CEO to Present TechKnow Invest Roadshow in MelbourneJuly 21, 2026 | tipranks.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Immuron CEO, Steven Lydeamore presentation at Kalkine Media WebinarJuly 20, 2026 | markets.businessinsider.comImmuron Showcases Oral Antibody Platform in July 20 Investor PresentationJuly 20, 2026 | tipranks.comImmuron Reports FY26 Global Sales Up 6% on Strong Travelan Growth in Australia and the U.S.July 16, 2026 | quiverquant.comQSee More Immuron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immuron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuron and other key companies, straight to your email. Email Address About ImmuronImmuron (NASDAQ:IMRN) Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.View Immuron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX: Love the Company, But the Stock Is a Harder CallAMD’s Post-Earnings Drop May Be the Opportunity Investors WantedMeta’s Earnings Drop Shows Wall Street Wants More Than Ad GrowthUlta's Growth Is Real, But So Are the RisksBWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth StoryCoreWeave Powers Up: The Asia Infrastructure GrabPalantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started? Upcoming Earnings Airbnb (8/6/2026)Warner Bros. Discovery (8/6/2026)Monster Beverage (8/6/2026)Canadian Natural Resources (8/6/2026)ConocoPhillips (8/6/2026)Cheniere Energy (8/6/2026)Petroleo Brasileiro S.A.- Petrobras (8/6/2026)Targa Resources (8/6/2026)Aflac (8/6/2026)Howmet Aerospace (8/6/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
